Kiniksa Pharmaceuticals Set to Release Q4 2025 Earnings on February 24

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) is preparing to announce its Q4 2025 earnings on February 24, 2026, before the market opens. Analysts anticipate that the company will report earnings of $0.37 per share and projected revenue of $200.855 million for the quarter. The earnings call is scheduled for 8:30 AM ET, providing an opportunity for interested parties to gain insights into the company’s financial performance.

The stock of Kiniksa Pharmaceuticals opened at $47.77 on Friday, reflecting a 1.3% increase. The company has a market capitalization of $3.62 billion, with a price-to-earnings ratio of 106.16 and a beta of 0.06. Over the past year, the stock has fluctuated between a low of $18.25 and a high of $47.86, indicating significant volatility.

Insider Trading Activity

Recent insider trading activity at Kiniksa Pharmaceuticals has drawn attention. Director Barry D. Quart sold 2,690 shares on February 12, 2026, at an average price of $45.00, amounting to a total transaction value of $121,050. Following this sale, Quart retains 12,546 shares, valued at approximately $564,570, which represents a 17.66% decrease in his ownership.

Additionally, Chief Financial Officer Mark Ragosa sold 17,845 shares on February 9, 2026, at an average price of $43.28, totaling $772,331.60. After this transaction, Ragosa holds 12,086 shares, valued at about $523,082.08, reflecting a 59.62% decrease in his position. In the last 90 days, insiders have sold a total of 123,823 shares, valued at $5,244,967. Corporate insiders currently own 53.48% of the company’s stock.

Analyst Ratings and Market Response

Brokerage firms have recently issued various reports on Kiniksa Pharmaceuticals. Zacks Research downgraded the stock from a “hold” to a “strong sell” rating on January 13, 2026. Conversely, Canaccord Genuity Group initiated coverage with a “buy” rating and a price target of $62.00. The Goldman Sachs Group raised its price target from $45.00 to $55.00 and maintained a “buy” rating. Weiss Ratings reaffirmed a “hold (c)” rating, while Wedbush increased its price target from $48.00 to $50.00 with an “outperform” rating.

Currently, seven investment analysts have rated Kiniksa with a “buy” rating, one has issued a “hold,” and one has given a “sell” rating. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a target price of $53.71, reflecting a generally optimistic outlook from analysts.

Kiniksa Pharmaceuticals, headquartered in Lexington, Massachusetts, focuses on developing therapeutics for patients with life-threatening immune-mediated diseases. Since its founding in 2013, the company has emphasized a patient-centric approach, aiming to address complex conditions with significant unmet medical needs. Its lead product, Ilaris (canakinumab), is an interleukin-1β blocker used to treat various inflammatory conditions.

As Kiniksa prepares for its upcoming earnings report, market observers will closely monitor the results, potentially impacting stock performance and investor sentiment in the biopharmaceutical sector.